Merck (MRK) Cash from Financing Activities (2009 - 2026)

Merck has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$3.0 billion for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 48.2% year-over-year to -$3.0 billion; the TTM figure through Mar 2026 stood at $852.0 million (up 108.54% YoY), while the FY2025 annual figure was -$1.9 billion, up 72.67% from the prior year.
• Cash from Financing Activities slipped to -$3.0 billion in Q1 2026, from $4.8 billion in the prior quarter.
• Over the last five years, Cash from Financing Activities for MRK reached as high as $4.8 billion in Q4 2025 and fell as low as -$5.8 billion in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$2.4 billion (2024), against an average of -$1.5 billion.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 311.48% — and 2025, when it slumped 392.43%.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.6 billion in 2022, then sank by 44.47% to -$2.2 billion in 2023, then tumbled by 34.03% to -$3.0 billion in 2024, then surged by 257.89% to $4.8 billion in 2025, then tumbled by 162.74% to -$3.0 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$3.0 billion, $4.8 billion, and $2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.